Sort   by:  
 Page size 
UnknownRELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Not available
S-EPMC8763844 | biostudies-literature
UnknownRELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.
Not available
S-EPMC10832259 | biostudies-literature
UnknownExploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Not available
S-EPMC7003392 | biostudies-literature
UnknownRELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Not available
S-EPMC9662911 | biostudies-literature
UnknownSerum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Not available
S-EPMC8039038 | biostudies-literature
UnknownX Chromosome Dosage Influences DNA Methylation Dynamics during Reprogramming to Mouse iPSCs.
Not available
S-EPMC5995367 | biostudies-literature
UnknownLentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.
Not available
S-EPMC12465018 | biostudies-literature
UnknownRamucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Not available
S-EPMC7360144 | biostudies-literature
UnknownNanoparticles systemically biodistribute to regenerating skeletal muscle in DMD.
Not available
S-EPMC10463982 | biostudies-literature
UnknownStage-specific regulation of reprogramming to induced pluripotent stem cells by Wnt signaling and T cell factor proteins.
Not available
S-EPMC3700671 | biostudies-literature
Sort   by:  
 Page size